Drug Profile

PRO 302 - Proterris

Alternative Names: PRO-302 - Proterris

Latest Information Update: 31 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Proterris
Class Anti-inflammatories; Antifibrotics; Cytoprotectives; Inorganic carbon compounds
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

14 Oct 2025 Preclinical trials in Reperfusion injury in Portugal (Inhalation), prior to October 2025 (Proterris pipeline, October 2025)
14 Oct 2025 Proterris announces intention to submit IND to regulatory body for Reperfusion injury in 2H 2025
14 Oct 2025 Proterris plans a phase Ib trial for Reperfusion injury (Prevention) (Inhalation) (Proterris pipeline, October 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com